Abstract:Macrophages are important effector cells in inflammatory responses. They are involved in bacterial infections and autoimmune diseases but also in the low grade inflammation associated with obesity and metabolic syndrome. Macrophages also have homeostatic functions and they activate healing process associated with inflammation and tissue injury [1-3]. To achieve these multiform tasks, macrophages are programmed to display distinct phenotypes in response to environmental signals [2-5]. For example, Th1 cytokine interferon γ (IFNγ) and toll-like receptor 4 (TLR4) ligand lipopolysaccharide (LPS) trigger classical, i.e. type M1, activation of macrophages, which is typical for bacterial infections and autoimmune reactions [6]. On the other hand, Th2 cytokines interleukin (IL) 4 and 13 trigger alternative, i.e. type M2, activation, which is associated with wound healing but also with the aberrant immune responses associated with overactivation of fibroblasts and subsequent fibrosis [6,7]. Classical activation of macrophages leads to the release of proinflammatory and antimicrobial factors including IL-6, IL-12, tumour necrosis factor (TNF) and nitric oxide (NO) produced by inducible nitric oxide synthase (iNOS) pathway. On the other hand, alternatively activated macrophages express factors that have been associated with recognition of extracellular pathogens and/or stimulation of fibroblasts. Some of Abstract: Peroxisome proliferator-activated receptor (PPAR) agonists, fibrates and thiazolidinediones, are commonly used drugs in the treatment of dyslipidemia and diabetes. Their targets, PPARα and PPARγ, have also been shown to have a role in the regulation of inflammatory responses linking metabolism and inflammation. In the present study we investigated the effects of PPAR agonists on macrophage activation. In addition to the proinflammatory classical activation, we also focused on interleukin (IL) 4 and 13 -induced alternative activation which is a significant macrophage phenotype in tissue repairing processes and in fibrosing diseases. PPARα agonists GW7647 and fenofibrate as well as PPARγ agonist GW1929 inhibited lipopolysaccharide-induced classical macrophage activation and production of the characteristic biomarkers of this phenotype, i.e. IL-6 and nitric oxide, in murine J774 macrophages. Remarkably, the PPARα agonists also inhibited IL-4 and IL-13 –induced expression of alternative activation markers arginase-1, fizz1 and mannose receptor 1 whereas the PPARγ agonist GW1929 enhanced their expression in J774 macrophages. The PPARα agonists GW7647 and fenofibrate also attenuated the production of alternative activation markers chemokine (C-C motif) ligand 13 and plateletderived growth factor in human THP-1 macrophages. The present findings show that PPARα and PPARγ agonists differently regulate classical and alternative macrophage phenotypes. Furthermore, PPARα activation was introduced as a novel concept to down-regulate alternative macrophage activation indicating that PPARα agonists have therapeutic potential in conditions associated with Research Article Open Access

Leptin down-regulates peroxisome proliferator-activated receptor γ (PPARγ) mRNA levels in primary human monocyte-derived macrophages

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

High Density Lipoprotein Suppresses Lipoprotein Associated Phospholipase A2 in Human Monocytes-Derived Macrophages Through Peroxisome Proliferator-Activated Receptor-Γ Pathway.

Inhibitory Effect of Peroxisome Proliferator Activated Receptor γ Ligands on Secretion of Inflammatory Cytokine and Matrix Metalloproteinase in Macrophages and Foam Cell

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Oxhdl Decreases the Expression of CD36 on Human Macrophages Through PPARγ and P38 MAP Kinase Dependent Mechanisms

Medium-chain fatty acids modify macrophage expression of metabolic and inflammatory genes in a PPAR β/δ-dependent manner

Effect of PPARα Ligands on Secretion of Inflammatory Cytokines in Foam Cells

Central Actions of Leptin Induce an Atrophic Pattern and Improves Heart Function in Lean Normoleptinemic Rats via PPARβ/δ Activation

[AdipoRon Effect on Expression of Lipid Metabolism Genes in Cultured Human Primary Macrophages]

Sterol regulatory element binding proteins downregulate LDL receptor-related protein (LRP1) expression and LRP1-mediated aggregated LDL uptake by human macrophages

Peroxisome proliferator-activated receptor gamma regulates interleukin-6 induced lipoprotein(a) gene expression in human HepG2 cells

Peroxisome proliferator-activated receptor alpha and gamma agonists differently regulate classical and alternative macrophage activation

Oxygenized low density lipoprotein down-regulates the TRPV4 protein expression of macrophage through activation of peroxisome proliferator-activated receptor γ

Downregulation of peripheral lipopolysaccharide binding protein impacts on perigonadal adipose tissue only in female mice

Inhibition of Macrophage CD36 Expression and Cellular Oxidized Low Density Lipoprotein (oxldl) Accumulation by Tamoxifen: A PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (Ppar)γ-Dependent MECHANISM.

Changes in Lipid Metabolism Enzymes in Rat Epididymal Fat after Chronic Central Leptin Infusion Are Related to Alterations in Inflammation and Insulin Signaling

Recombinant human cachectin/tumor necrosis factor but not interleukin-1 alpha downregulates lipoprotein lipase gene expression at the transcriptional level in mouse 3T3-L1 adipocytes

PGC1α enhances macrophage efferocytosis in ox-LDL-stimulated RAW264.7 cells by regulating the NLRP3/PPARα axis

Effects of PPARs Agonists on Cardiac Metabolism in Littermate and Cardiomyocyte-Specific PPAR-γ-knockout (CM-PGKO) Mice.

Inhibitory Effect of Ppar on the Expression of Emmprin in Macrophages and Foam Cells